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Sustained drug therapy offers potential advantages, compared to conventional dos-
age forms, such as avoiding patient compliance problems, improving clinical efficacy, re-
ducing fluctuations in blood and providing cost effectiveness (1). Matrix tablets are
among the most widely used oral controlled release systems containing a therapeutic
agent, homogenously dissolved or dispersed, in a compressed water-swellable core (2).
Natural materials like ispaghula husk, guar gum and alginates are relatively inex-
pensive, nontoxic, and easily available. Ispaghula husk (dried seed coat of Plantago ovata
(Plantaginaceae)) and guar gum have been used as matrixing agents by researchers for
the development of modified release dosage forms (3). In general, such materials are un-
suitable for tabletting because of their elasticity, poor flow and compression properties.
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The objective of the present investigation was to prepare
and evaluate an ispaghula husk based directly compre-
ssible (DC) adjuvant that can be used as matrixing agent
using an agglomeration technique. Addition of hydroxy-
propyl methylcellulose was found necessary to improve
cohesion. Lactose (X1), calcium hydrogen phosphate di-
hydrate (X2) and Avicel PH101 (X3), used along with is-
paghula in preparation of agglomerates, were selected as
three independent variables in a simplex lattice design
affecting compressional and dissolution characteristics of
the drug from the DC adjuvant. The agglomerates were
evaluated for their flow properties. Tablets were prepared
using 70% agglomerates and 30% acetaminophen, a poorly
compressible drug, and were subjected to in vitro drug re-
lease study. Amounts of the drug released at the end of
60 min (Y60), 300 min (Y300) and 480 min (Y480) were
selected as dependent variables in a simplex lattice de-
sign. Batch IH05 that contained lactose and calcium hy-
drogen phosphate dihydrate in a 1:2 ratio could control
the release for 12 hours and thus form the basis for twice
a-day-dosing.
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Ispaghula husk is official in IP, BP and USP. It is used in food and pharmaceuticals at a
dose level of 5–7 g twice a day. Ispaghula husk forms a thick swollen gel when kept in
contact with water. Additionally, it is fibrous in nature and is poorly compacted (3).
Granulation of the drug and matrixing agent along with the diluents is usually ne-
cessary to improve the flowability and compressibility, especially when a high-speed
tabletting machine is used. Attempt has been made to provide a method by which the
drug can be simply mixed with the matrixing agent and thereafter directly compressed
into tablets without granulation. This requires modification of the available matrixing
agents to provide tablet materials with ideal properties for tablet production. Researchers
have not explored the use of ispaghula husk in the preparation of directly compressible
matrixing agents and hence the present study was undertaken.
Modification by co-processing was adopted because the product here is physically
modified in a special way, so that it does not lose its chemical structure and stability.
This type of modification is cost effective for developing the product, with added value
of its functionality.
In this investigation, ispaghula was co-processed with lactose, Avicel PH101 and
calcium hydrogen phosphate dihydrate (CHPD) using a simple agglomeration method
to prepare a directly compressible (DC) matrixing agent. The slow release excipient was




Ispaghula husk was purchased from a local pharmacy. Lactose and CHPD were ob-
tained as gift samples from Bombay Tablets, India. Avicel PH101 and polyvinylpyrroli-
done were received as gift samples from Torrent Research Centre, India. Hydroxypropyl
methylcellulose (HPMC, Methocel K100 LV) was a gift sample from Colorcon Asia Pvt.
Ltd., India.
Simplex lattice design for preparation of agglomerates
Simplex lattice design was utilized in the present study. In this design, three factors
were evaluated and exprerimental trials were carried out in ten different combinations.
Lactose, CHPD and Avicel PH101 were agglomerated along with HPMC and ispaghula
husk powder (80–100 mesh, 177–149 mm) using an alcoholic solution of polyvinylpyrro-
lidone (4 g in 20 mL). The batch size was 50 g. Ispaghula and HPMC were used in the
quantity of 10 g each. The rest 30 g were formed of the three excipients in the amounts
given in Table I. The amounts of lactose (X1), CHPD (X2) and Avicel PH101 (X3) were se-
lected as independent variables.
The agglomerates were evaluated for the angle of repose and Carr’s index. Angle of
repose was measured by the fixed funnel method (4). The percentage compressibility
(Carr’s index) was calculated as 100 times the ratio of the difference between tapped
density and bulk density to tapped density (5).
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Preparation of blank tablets
The agglomerates were blended with 1% magnesium stearate for 2 min. Tablets
were prepared on a single punch tablet machine (Cadmach Machinery Private Limited,
India). The average tablet mass was 500 mg. The hardness of tablets (n = 10) was mea-
sured using a Dr. Scleuniger Pharmatron Tablet Tester 8M (Solothurn, Switzerland). Fri-
ability was evaluated as the percentage mass loss of 20 tablets tumbled in a friabilator
(model EF2, Electrolab, India) for 4 min at 25 rpm. The tablets were then dedusted, and
the mass loss caused by fracture or abrasion was recorded as percentage friability (6).
Preparation of tablets with acetaminophen
Tablets containing 30% acetaminophen were prepared. Tablets (n  50) containing
acetaminophen (150 mg) and agglomerates (350 mg), magnesium stearate (5 mg) were
prepared and evaluated for hardness and friability.
In vitro dissolution study
In vitro dissolution study of the tablets was carried out in phosphate buffer (pH 5.8,
900 mL, 37 ± 0.5 °C) by using a USP apparatus (model TDT – 60T, Electrolab, India) fit-
ted with paddles (50 rpm) (6). Samples (5 mL) were withdrawn at predetermined time
intervals, filtered through 0.45-mm filter, and assayed at 246 nm using a UV/VIS spectro-
photometer (Jasco V530, Japan) to determine the percentage of drug released. The same
volume (5 mL) of fresh dissolution medium (37 ± 0.5 °C) was replenished immediately
after the sample was withdrawn.
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Table I. Actual and transformed values of ten different formulations as per the simplex lattice design
Batch
Formulation components (g) Transformed fraction
X1 X2 X3 X1 X2 X3
IH01 30 0 0 1 0 0
IH02 0 30 0 0 1 0
IH03 0 0 30 0 0 1
IH04 20 10 0 0.66 0.33 0
IH05 10 20 0 0.33 0.66 0
IH06 0 20 10 0 0.66 0.33
IH07 0 10 20 0 0.33 0.66
IH08 10 0 20 0.33 0 0.66
IH09 20 0 10 0.66 0 0.33
IH10 10 10 10 0.33 0.33 0.33
X1 – lactose, X2 – calcium hydrogen phosphate dihydrate, X3 – Avicel PH101
RESULTS AND DISCUSSIONS
Addition of directly compressible excipients has been used by researchers not only
to alter the tablet size but also to improve the compaction and mechanical properties of
the tablet (7). Lactose, CHPD and Avicel PH101 were therefore expected to enhance flo-
wability and compressibility. Addition of HPMC improved cohesion during the granu-
lation operations to enlarge the particle size of granules but also during compression to
increase the hardness of tablets. The binding ability of HPMC resulted in stronger adhe-
sion between granules (8). Agglomerates of the simplex lattice design were evaluated
for the angle of repose and compressibility index. All the batches exhibited the angle of
repose less than 40° and the percentage compressibility index less than 20, indicating
fair flow (Table II). Blank tablet hardness was in the range of 50–80 N. The friability va-
lue for all the batches was found to be less than 1%. Thus, the agglomerates possessed
characteristics that make them suitable for direct compression.
Dilution potential is the ability of the excipient to retain its compressibility even
when diluted with a non-compressible material. The agglomerates of the experimental
batches were compressed with 30% acetaminophen, a poorly compressible drug. The
hardness of these tablets was 40 to 60 N and friability values were less than 1% for all
the experimental batches. This indicates that inspite of dilution with acetaminophen, the
tablets fulfilled the hardness and friability criteria.
The ability of the DC matrixing agent to provide controlled release was tested using
an in vitro dissolution study. The in vitro dissolution study of the tablets was carried out
to find the amount of drug released at the end of 60 min (Y60), 300 min (Y300) and 480
min (Y480). A first-order statistical model incorporating interactive terms was utilized to
evaluate these responses:
Y = b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b123X1X2X3
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Table II. Technological and dissolution parameters for the simplex lattice design
Batch AR (°) CI (%) Y60 (%) Y300 (%) Y480 (%)
IH01 36.25 12.90 28.15 72.72 93.55
IH02 38.33 14.29 17.02 48.72 65.21
IH03 26.56 19.35 29.65 78.46 98.46
IH04 30.20 12.60 28.03 67.28 81.90
IH05 31.00 14.50 22.65 58.52 76.59
IH06 25.90 19.60 26.59 60.80 72.70
IH07 25.00 19.96 28.95 68.57 85.47
IH08 23.00 19.67 33.52 74.25 95.46
IH09 26.00 18.50 30.18 76.76 99.97
IH10 26.00 17.50 45.46 80.97 99.55
AR – angle of repose, CI – compressibility index.
Y60, Y300 and Y480 indicate the percentage of drug dissolved after 60, 300 and 480 minutes, respectively.
where bi (i = 1, 2, 3…123) is the estimated coefficient for the factor Xi. Multiple linear re-
gression analysis was done using the Design Expert® 6.0.5 Trial (Statease statistical soft-
ware package). The main effects (X1, X2 and X3) represent the average results of chang-
ing one factor at a time from its low to its high value. Interactions X1X2, X2X3, X1X3 and
X1X2X3 show how the response changes when the two or three factors change simulta-
neously.
Results of the multiple regression analysis are shown in Table III. Avicel PH101 and
lactose had higher values of the coefficient in the equation used to describle Y60, Y300
and Y480 while calcium hydrogen phosphate had a lower value. Avicel PH101 had a
stronger effect than lactose in increasing the dissolution rate, as indicated by the equa-
tion coefficients. Lactose, being freely soluble, will dissolve and provide a pathway for
diffusion of the drug and erosion of the matrix, leading to fast release of the drug from
the matrix tablet. Although Avicel PH101 and CHPD are water-insoluble, Avicel PH101
has disintegrating properties that promote disintegration of the matrix and therefore the
matrix will easily erode compared to CHPD. In addition, CHPD tablets do not disinte-
grate readily. Therefore, matrices containing CHPD would have less tendency to erode
compared to Avicel PH101 and consequently slower release rate. Ladipus and Lordi (9)
postulated that the presence of high levels of insoluble diluents reduced release rates by
increasing the tortuosity of the matrix, whereas the addition of a soluble diluent (lac-
tose) merely reduced the tortuosity of the matrix, thereby increasing the dissolution
rates. Use of a combination of lactose/Avicel PH101 and CHPD produced drug release
profiles of intermediate duration. The dissolution profiles of batch IH05 (containing 33%
lactose) and IH06 (containing 33% Avicel PH101) which contain 66% CHPD were essen-
tially similar similarity factor (f2 = 71.26). When CHPD was present at lower levels
(33%), IH04 (containing 66% lactose) and IH07 (containing 66% Avicel PH101), no appre-
ciable difference in dissolution profile was found (f2 = 84.27), indicating that the pres-
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Table III. Results of the regression analysis for dependent variables
Dependent
variables
b1 b2 b3 b12 b23 b31 b123 R2
Y60 27.99 17.03 29.80 14.02 21.07 14.90 426.45 0.9853
Y300 73.46 48.89 77.55 10.72 9.64 3.47 345.28 0.9866
Y480 93.85 65.53 97.85 1.63 –8.20 12.98 388.70 0.9798
Table IV. Results of the model fitting of batch IH05




Korsmeyer and Peppas 0.9872 6.45
Hixon-Crowell 0.9802 18.91
Weibull 0.9951 1.74
ence of lactose or Avicel PH101 does have an effect depending on their proportion and
the two are interchangeable.
An ideal modified release dosage form, intended to be given twice a day, should re-
lease the loading dose (25%) in the first hour and later (up to 12 h) the remaining drug
should be released at a constant rate (6.82% h–1) (3). The ideal release profile was calcu-
lated as per the set criteria. According to the US FDA guidelines for similarity factor (f2)
calculations, two dissolution profiles are considered as identical if the calculated f2 va-
lue is greater than or equal to 50. This value is calculated considering 10% deviation be-
tween a reference and a test formulation. The value of f2 is equal to 100 when the two
dissolution profiles are identical.
The dissolution profile of batch IH05, containing lactose and CHPD in 1:2 ratio
along with ispaghula husk powder and HPMC, was similar to the ideal release profile
(f2 = 64.40 corresponding to 5% difference). Fig. 1 shows the dissolution profile of batch
IH05 and the ideal release profile.
The ideal values for a twice-a-day drug formulation as per the above mentioned cri-
teria for Y60, Y300 and Y480 are 25.0%, 59.1% and 72.7% respectively. To widen the sco-
pe of selection, the following constraints were chosen for the selection of acceptable bat-
ches: 15% < Y60 < 25%, 55% < Y300 < 65%, 70% < Y480 < 80%. Contour plots were
drawn using the above-mentioned constraints for dissolution in 60 (Y60), 300 (Y300) and
480 (Y480) min as per the respective equations. Optimization was performed by super-
imposing the three contour plots and locating the area of interest (Fig. 2). Any combina-
tion that falls in this area (shaded black) will satisfy the selected constraints of dissolu-
tion. It is worthwhile noting that batch IH05 lies in this area.
The dissolution data of batch IH05 was fitted to zero-order, first-order, Higuchi (10),
Hixson-Crowell (11), Korsmeyer and Peppas (12), and Weibull models (13). The method
of Bamba et al. (14) was adopted for deciding on the most appropriate model. The results
of F-statistics were used to select the most appropriate model. The release profile of
batch IH05 fitted best to the Weibull model (F = 1.74). This superiority is statistically in-
significant with the Korsmeyer and Peppas model (F = 6.45) and Higuchi model (F =
6.60), as shown by the goodness-of-fit test. But, priority should be given to the model
with the lowest F-value. Thus, it may be concluded that drug release of acetaminophen
from the matrix tablet is best explained by the Weibull model. The value of the slope for
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Fig. 1. Comparison of in vitro
dissolution profiles of batch
IH05 and the ideal release
profile (mean ± SD; n = 3).
the Korsmeyer and Peppas model is 0.6232, indicating that the drug was released by dif-
fusion of an anomalous type.
CONCLUSIONS
The present study indicates that ispaghula husk can be used as matrixing agent
along with lactose, CHPD and Avicel PH101 to produce a DC adjuvant with sustained
release properties. A proper proportion of the release enhancer (lactose/Avicel PH101)
and release retardant (CHPD) can be selected from the contour plot to produce the de-
sired dissolution profile. The statistical technique thus enables formulation scientists to
examine more than one independent variable at a time. Desirable goals can be obtained
by a systematic approach in the shortest possible time.
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S A @ E T A K
Priprava i vrednovanje matriksnog agensa na bazi
ispagule za kontrolirano osloba|anje
ANITA N. LALWANI i JOLLY R. PARIKH
Cilj rada bila je priprava i vrednovanje pomo}ne tvari za izravnu kompresiju dobi-
vene iz ljuski ispagule, primjenjive u izradi pripravaka metodom aglomeracije. Dodatak
hidroksipropil metilceluloze bio je neophodan za pove}anje kohezije. U pripravi aglo-
merata s ispagulom upotrebljeni su laktoza (X1), kalcijev hidrogenfosfat dihidrat (X2) i
Avicel PH101 (X3). U eksperimentalnom dizajnu (simplex lattice design) te tri tvari izabra-
ne su kao nezavisne varijable. Prou~avan je njihov utjecaj na kompresibilnost i osloba-
|anje ljekovite tvari iz pripravka dobivenih izravnom kompresijom te svojstva te~nosti
aglomerata. Tako dobiveni aglomerati upotrebljeni su za pripravu tableta te{ko kompre-
sibilne tvari acetaminofena (omjer aglomerata i ljekovite tvari 7:3). Koli~ine oslobo|ene
tvari in vitro pri kraju 60 min (Y60), 300 min (Y300) i 480 min (Y480) bile su zavisne vari-
jable. Iz pripravka IH05 koji sadr`i laktozu i kalcijev hidrogenfosfat dihidrat u omjeru
1:2 kontrolirano se osloba|a ljekovita tvar tijekom 12 sati, {to je dobar temelj za dozira-
nje dva puta dnevno.
Klju~ne rije~i: simplex lattice design, ljuske ispagule, izravno kompresibilan, matriksna tvar, faktor
sli~nosti
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